Navigation Links
Supratek Pharma Inc. announced today that under the Special Protocol
Date:11/28/2007

Assessment (SPA) process, it has obtained agreement with the United States Food and Drug Administration (FDA) for the design of its pivotal study protocol for SP1049C for the treatment of metastatic adenocarcinoma of the

upper gastrointestinal tract

MONTREAL, Nov. 28 /PRNewswire/ - The randomized, multicenter Phase III pivotal clinical trial will compare SP1049C plus Best Supportive Care (BSC) versus BSC alone for the treatment of patients with advanced adenocarcinoma of the esophagus, gastroesophageal junction and stomach who have failed adjuvant or 1st or 2nd line chemotherapy. Supratek Pharma is the sponsor of the international trial and its Clinical Oncology team will direct the clinical development program.

Oleg Romar, President and Chief Executive Officer, said, "We are pleased that the FDA has accepted our Phase III clinical protocol for SP1049C. This acceptance is a significant milestone and represents a critical step in the advancement of our clinical program. We believe that SP1049C, a novel anthracycline, may be a breakthrough treatment for this patient population. FDA's agreement in writing to a protocol reviewed under this process is considered binding on the review division of the FDA, providing that the protocol is followed and no substantial scientific issues arise regarding the safety or efficacy of the drug after the testing has begun."

"In the SPA communication, the FDA advised that the clinical design and analysis plan of our submitted protocol are suitable to provide evidence of safety and efficacy to support a new drug application (NDA) for SP1049C for the treatment of cancer of the upper gastrointestinal tract," said Dr. Christopher E. Newman, Vice President and Chief Medical Officer of Supratek Pharma. "The protocol for this trial was optimized with contributions from world opinion leaders in oncology. We look forward to the launching of this important pivotal study."

About SP1049C

-------------

Supratek's proprietary lead anticancer drug candidate, SP1049C, is the most advanced nanomedicine drug candidate that is based on polymer technology. This drug is a Biotransport(TM) composition of poloxamers with one of the most potent cytotoxic drugs, doxorubicin. SP1049C has been shown, in pre-clinical and clinical development, to have much higher efficacy and a novel mechanism of action against chemoresistant tumors in which the original drug is inactive. SP1049C has also obtained an Orphan Drug designation from the FDA for the treatment of esophageal carcinoma.

About Supratek Pharma Inc.

--------------------------

Supratek Pharma is an emerging pharmaceutical company focused on the treatment of drug resistant and metastatic cancers. The company has seven clinical-stage proprietary products in its pipeline. The next product in line for clinical development is SP-MET-X1. It is based on the Company's potential breakthrough discovery of a biochemical pathway and target consistently involved in metastasis formation and cancer progression. SP-MET-X1, the first drug developed in this new therapeutic class, is a novel use of an existing non-cancer drug that is specific to the new validated target.


'/>"/>
SOURCE Supratek Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Church, VA (PRWEB) , ... June 28, 2017 , ... ... http://www.fdanews.com/fdaeumdregs      , No matter on which side of the Atlantic devicemakers ... medical device regulations they have to follow. , In addition to the full text ...
(Date:6/28/2017)... IL (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a ... Park, Illinois, took over the post of 2nd Vice President for the Illinois State ... was installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. ... a two year study conducted by the University of Saskatchewan in partnership with ... remediating potash brine-impacted groundwater. As a part of the study, batch adsorption experiments ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom ... technical specifications . , 2017 has seen an explosion of token launches by ... offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/10/2017)... Burchfield, DPM, is recognized by Continental Who,s Who as a Pinnacle ... Alabama . Dr. Burchfield serves as a ... 20 years of experience, as well as expertise in the areas ... "The podiatry professional   ... welcome you to his practice," the company,s website states. "We want ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
Breaking Medicine Technology: